Development
Cytokinetics, Incorporated
CYTK
$36.16
-$0.42-1.15%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -136.90M | -129.42M | -128.64M | -131.29M | -137.38M |
| Total Depreciation and Amortization | 6.34M | 1.85M | 1.86M | 1.85M | 1.66M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.65M | 29.88M | 29.08M | 26.33M | 20.69M |
| Change in Net Operating Assets | 44.88M | 1.48M | -24.10M | -19.17M | 16.84M |
| Cash from Operations | -74.04M | -96.21M | -121.81M | -122.29M | -98.19M |
| Capital Expenditure | -77.00K | -220.00K | -717.00K | -402.00K | -3.21M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -81.33M | 73.26M | 82.85M | 165.90M | 32.45M |
| Cash from Investing | -81.41M | 73.04M | 82.13M | 165.50M | 29.25M |
| Total Debt Issued | -- | -- | -- | -- | 0.00 |
| Total Debt Repaid | -222.00K | -217.00K | -212.00K | -207.00K | -105.00K |
| Issuance of Common Stock | 169.02M | 4.44M | 5.69M | 3.55M | 3.60M |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | -10.52M | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 50.00M | -- | -- | 26.39M |
| Cash from Financing | 168.80M | 54.22M | 5.48M | -7.18M | 29.89M |
| Foreign Exchange rate Adjustments | -20.00K | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 13.33M | 31.05M | -34.20M | 36.03M | -39.06M |